

WELCOMING ADDRESS:



DENIS HORGAN

**Executive Director, European Alliance
for Personalised Medicine**

A TRULY COLLABORATIVE GATHERING

150+ participants on-site

→ Bringing together policymakers, researchers, industry, and patient voices under one roof.



80+ distinguished speakers

→ Experts shaping the future of personalised medicine through plenaries, workshops, and debates.


450+ online participants

→ Extending the conversation beyond the conference hall, ensuring global reach and inclusivity.

Together, this diverse community will exchange ideas, challenge assumptions, and co-create the roadmap for Europe's personalised healthcare future.




ONE VISION, MANY VOICES



European Alliance for
Personalised Medicine



- Our journey to Vision Europe 2030 celebrates unity of purpose, but we must also embrace diverse needs, expectations, and perspectives.
- Personalised medicine thrives at the intersection of shared goals and individual differences.



BREAKING BARRIERS TO ACCESS



- Access remains a key challenge.
- Too often, those most in need cannot fully participate due to barriers in infrastructure, healthcare access, or social determinants.
- In Vision Europe 2030, our task is to ensure inclusion and equal opportunity for all patients.





INVESTING TODAY FOR TOMORROW'S HEALTH



- Initial investments in research and innovation may seem costly.
- But personalised medicine pays for itself by driving better outcomes, efficiency, and long-term sustainability.



European Alliance for
Personalised Medicine





EVIDENCE FIRST, FLEXIBILITY ALWAYS



European Alliance for
Personalised Medicine

- We must remain evidence-based, not guided by superstition or outdated models.
- At the same time, healthcare systems must stay flexible—to adapt to disruptive technologies and evolving patient needs.




BEYOND ONE-SIZE-FITS-ALL



European Alliance for
Personalised Medicine

- Personalised medicine is not one-size-fits-all.
- It is not about “take one of mine”, but about tailoring treatments to each patient’s biology, environment, and values.





DATA: THE LIFELOOD OF PERSONALISED MEDICINE



- **Big data, small data, each patient's data matters.**
- **Unlocking the potential of both population-level insights and individual contributions is essential for next-gen treatments.**



European Alliance for
Personalised Medicine



AGENDA: DAY 1 – SEPTEMBER 2ND, 2025



Time	Session Title	Moderator / Chair
09.15 – 10.30	Tech for Equity: Catalyzing Innovation in High-Income Cancer Systems	Jose M. Martin-Moreno, University of Valencia & Spanish Economy and Health Foundation
10.30 – 11.30	Democratizing Trials – Blueprint for Inclusive Innovation	Antoni Moliner Montseratt, ALAN – Maladies Rares Luxembourg
12.00 – 13.00	Precision Oncology 2.0 – From RCT-Centered Models to Innovation-Ready Systems	Jose M. Martin-Moreno, University of Valencia & Spanish Economy and Health Foundation
14.00 – 15.00	Public–Private Power Plays – Building Sustainable Partnerships	Josep Figueras, European Observatory on Health Systems and Policies
15.30 – 16.30	Spotlight 1: Bridging the Innovation Gap – Precision Cardiology	Donna Fitzsimons, Queen's University Belfast, former ESC Board Member
16.30 – 17.30	Spotlight 2: Bridging the Innovation Gap – Precision Neurology	Frédéric Destrebecq, European Brain Council
18.45 – 22.00	Cocktail Reception & Working Dinner – Keep the Person in Personalised HealthCare (By Invitation Only)	Josep Figueras, European Observatory on Health Systems and Policies

AGENDA: DAY 2 – SEPTEMBER 3RD, 2025



Time	Session Title	Moderator / Chair
09.00 – 10.00	Innovation Without Access Is Failure – Delivering Genomic Equity	Jose M. Martin-Moreno, University of Valencia & Spanish Economy and Health Foundation
10.00 – 11.00	Data That Delivers – Building a Smarter, Sustainable Healthcare Data System	Antoni Moliner Montseratt, ALAN – Maladies Rares Luxembourg
11.30 – 12.30	Choose Europe, Back Health – Translating the Draghi Vision	Phil Hogan, Former EU Commissioner for Trade
14.00 – 15.00	Spotlight 3: Precision Frontiers in Chronic Disease – Global Strategy	Ruggero De Maria, Italian Alliance Against Cancer & Università Cattolica del Sacro Cuore, Rome
15.00 – 15.45	Screening Reimagined for a Digital, AI-Enabled Future	Elil Renganathan, Monash University Malaysia
15.45 – 16.30	Concluding Session – Toward a Technology-Driven Cancer Control Framework	Josep Figueras, European Observatory on Health Systems and Policies

OUR MODERATORS/CHAIR:



JOSE M. MARTIN-MORENO

Professor of Medicine and Public Health, University of Valencia & Chair of Innovative Health Management, Spanish Economy and Health Foundation



ANTONI MOLINER MONSERATT

Vice président - ALAN Vice President of the National Committee of the Rare Diseases Plan of Luxembourg



JOSEP FIGUERAS

Director Emeritus, European Observatory on Health Systems and Policies



FRÉDÉRIC DESTREBECQ

Executive Director, European Brain Council



DONNA FITZSIMONS


Head of Nursing & Midwifery, Queen's University Belfast & former ESC Board Member

OUR MODERATORS/CHAIR:



PHIL HOGAN

Former EU Commissioner for Trade



RUGGERO DE MARIA

President, Italian Alliance Against
Cancer (Alleanza Contro il
Cancro), Professor of Pathology,
Università Cattolica del Sacro
Cuore, Rome



ELIL RENGANATHAN

Professor, Public Health and Policy,
Jeffrey Cheah School of
Medicine and Health Sciences,
Monash University Malaysia

OUR RAPPORTEURS:



DENIS HORGAN

Executive Director, European Alliance
for Personalised Medicine



ELIL RENGANATHAN

Professor, Public Health and
Policy, Jeffrey Cheah School
of Medicine and
Health Sciences, Monash
University Malaysia



TILMAN KRUEGER

MSD, Director
Oncology Policy EU &
Pipeline



MUIRIS O'CONNOR

Assistant Secretary, Department of
Health, Ireland



MARILYS CORBEX

Senior Technical Officer, WHO Europe

TOGETHER, OVER THESE TWO DAYS, WE WILL:

- Explore disruptive technologies
- Democratize clinical trials
- Shape next-generation treatment paradigms
- Let us move from vision to reality, for patients, for science, for Europe.

